Does the media refer more to ESPR or NKTX?

In the previous week, Esperion Therapeutics and Esperion Therapeutics both had 4 articles in the media. Esperion Therapeutics' average media sentiment score of 1.42 beat Nkarta's score of 0.47 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NKTX or ANRO?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is NKTX or ANRO more profitable?

Nkarta's return on equity of -30.90% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Alto Neuroscience N/A -47.22% -38.81%

Which has stronger earnings & valuation, ANNX or NKTX?

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is ANNX or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Nkarta N/A -30.90% -24.20%

Which has better earnings & valuation, VOR or NKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is VOR or NKTX more profitable?

Vor Biopharma's return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Nkarta N/A -30.90% -24.20%

Does the media favor VOR or NKTX?

In the previous week, Nkarta had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.94 beat Nkarta's score of 0.47 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NKTX or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is NKTX or DSGN more profitable?

Nkarta's return on equity of -30.90% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer NKTX or DSGN?

In the previous week, Nkarta had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.04 beat Nkarta's score of 0.47 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nkarta (NKTX) Competitors

$2.83 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.80 -0.04 (-1.24%)

As of 04:03 AM Eastern

Compare

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

Should you buy Nkarta stock or one of its competitors? MarketBeat compares Nkarta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nkarta include Esperion Therapeutics (ESPR), Alto Neuroscience (ANRO), Annexon (ANNX), Vor Biopharma (VOR), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

How does Nkarta compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Esperion Therapeutics and Esperion Therapeutics both had 4 articles in the media. Esperion Therapeutics' average media sentiment score of 1.42 beat Nkarta's score of 0.47 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Esperion Therapeutics has higher revenue and earnings than Nkarta. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Esperion Therapeutics has a net margin of 0.12% compared to Nkarta's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Nkarta	N/A	-30.90%	-24.20%

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 74.76%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Esperion Therapeutics beats Nkarta on 8 of the 15 factors compared between the two stocks.

How does Nkarta compare to Alto Neuroscience?

Nkarta (NASDAQ:NKTX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, Nkarta had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Nkarta and 0 mentions for Alto Neuroscience. Nkarta's average media sentiment score of 0.47 beat Alto Neuroscience's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Neutral
Alto Neuroscience	Neutral

80.5% of Nkarta shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nkarta has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Nkarta's return on equity of -30.90% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Nkarta presently has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 31.36%. Given Nkarta's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nkarta is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Nkarta beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.

How does Nkarta compare to Annexon?

Annexon (NASDAQ:ANNX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

80.5% of Nkarta shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annexon presently has a consensus target price of $16.00, suggesting a potential upside of 191.28%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nkarta's return on equity of -30.90% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Nkarta	N/A	-30.90%	-24.20%

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 3 more articles in the media than Annexon. MarketBeat recorded 4 mentions for Nkarta and 1 mentions for Annexon. Annexon's average media sentiment score of 1.87 beat Nkarta's score of 0.47 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Very Positive
Nkarta	Neutral

Annexon has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Nkarta beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Nkarta compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Nkarta (NASDAQ:NKTX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Vor Biopharma's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Nkarta	N/A	-30.90%	-24.20%

In the previous week, Nkarta had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.94 beat Nkarta's score of 0.47 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vor Biopharma currently has a consensus price target of $42.25, indicating a potential upside of 162.42%. Nkarta has a consensus price target of $10.75, indicating a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Summary

Vor Biopharma beats Nkarta on 7 of the 11 factors compared between the two stocks.

How does Nkarta compare to Design Therapeutics?

Nkarta (NASDAQ:NKTX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Nkarta has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

80.5% of Nkarta shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nkarta's return on equity of -30.90% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Design Therapeutics	N/A	-33.07%	-31.29%

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 23.60%. Given Nkarta's higher possible upside, equities research analysts clearly believe Nkarta is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Nkarta had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.04 beat Nkarta's score of 0.47 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Design Therapeutics beats Nkarta on 7 of the 13 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$202.46M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-2.11	21.75	25.89	24.17
Price / Sales	N/A	334.18	547.76	101.00
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.64	8.31	10.75	6.38
Net Income	-$104.08M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.43%	1.93%	1.97%	-0.20%
1 Month Performance	-12.92%	-0.41%	-0.24%	-1.40%
1 Year Performance	70.48%	65.22%	34.39%	27.76%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	4.2487 of 5 stars	$2.83 flat	$10.75 +279.9%	+70.5%	$202.46M	N/A	N/A	140	Gap Down High Trading Volume
ESPR Esperion Therapeutics	2.7353 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+219.0%	$811.73M	$403.14M	N/A	200	Positive News
ANRO Alto Neuroscience	1.9454 of 5 stars	$22.93 +0.8%	$35.25 +53.7%	+1,044.3%	$804.71M	N/A	N/A	N/A	Gap Down
ANNX Annexon	3.6096 of 5 stars	$5.04 +2.9%	$16.00 +217.5%	+127.9%	$802.83M	N/A	N/A	60	Positive News Gap Down
VOR Vor Biopharma	2.3421 of 5 stars	$14.94 +3.1%	$42.25 +182.8%	-24.1%	$785.16M	N/A	N/A	140	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

How does Nkarta compare to Esperion Therapeutics?

Summary

How does Nkarta compare to Alto Neuroscience?

Summary

How does Nkarta compare to Annexon?

Summary

How does Nkarta compare to Vor Biopharma?

Summary

How does Nkarta compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

How does Nkarta compare to Esperion Therapeutics?

Does the media refer more to ESPR or NKTX?

Which has preferable valuation & earnings, ESPR or NKTX?

Which has more risk and volatility, ESPR or NKTX?

Do institutionals & insiders believe in ESPR or NKTX?

Is ESPR or NKTX more profitable?

Do analysts rate ESPR or NKTX?

Summary

How does Nkarta compare to Alto Neuroscience?

Does the media prefer NKTX or ANRO?

Do insiders and institutionals believe in NKTX or ANRO?

Which has more volatility and risk, NKTX or ANRO?

Is NKTX or ANRO more profitable?

Which has higher earnings and valuation, NKTX or ANRO?

Do analysts recommend NKTX or ANRO?

Summary

How does Nkarta compare to Annexon?

Do insiders & institutionals hold more shares of ANNX or NKTX?

Do analysts rate ANNX or NKTX?

Is ANNX or NKTX more profitable?

Which has stronger earnings & valuation, ANNX or NKTX?

Does the media favor ANNX or NKTX?

Which has more risk and volatility, ANNX or NKTX?

Summary

How does Nkarta compare to Vor Biopharma?

Is VOR or NKTX more profitable?

Does the media favor VOR or NKTX?

Do institutionals & insiders believe in VOR or NKTX?

Do analysts prefer VOR or NKTX?

Which has more volatility and risk, VOR or NKTX?

Which has better earnings & valuation, VOR or NKTX?

Summary

How does Nkarta compare to Design Therapeutics?

Which has more risk & volatility, NKTX or DSGN?

Do institutionals and insiders believe in NKTX or DSGN?

Is NKTX or DSGN more profitable?

Do analysts rate NKTX or DSGN?

Which has stronger valuation & earnings, NKTX or DSGN?

Does the media prefer NKTX or DSGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools